Announced Thu, 9 Jul · 20:06 IST
Bacil Pharma board approves Rights Issue of up to Rs 50 Crores
Corporate Actions View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.2%1-day move
₹38.36
prior close
₹39.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9———-2.2-2.2-3.9-3.8-4.8-14.3————
Up moveDown movePending
AI summary
Bacil Pharma's board approved a Rights Issue of equity shares for up to Rs 50 Crores. Authorised share capital will rise by Rs 45 Crores to Rs 65 Crores, subject to shareholder approval. Two independent directors, Mr Dinesh Chander Notiyal and Ms Avani Savjibhai Godhaniya, resigned. Purva Sharegistry, Axis Bank and Acuite Ratings were appointed as registrar, banker and monitoring agency. Issue price, entitlement ratio and record date are yet to be decided.
Likely market impact
Rights issue may dilute existing shareholders if they do not subscribe. Key terms like price and ratio not yet announced, so watch for further updates.